Moderna and Merck Phase 3 Data Shows Intismeran Plus Keytruda Cuts Risk of Melanoma Recur…
Phase 3 INTerpath-001 trial results show combining individualized mRNA therapy intismeran with Keytruda significantly lowered recurrence or death in resected melanoma.
In short
- The Phase 3 INTerpath-001 trial showed intismeran plus Keytruda cut the risk of melanoma recurrence or death by 42% compared to Keytruda alone.
- The customized therapy encodes up to 34 patient-specific neoantigens identified by sequencing tumors against healthy tissue.
- The treatment effect became more pronounced after six months, yielding a 58% reduction in recurrence or death risk in a sensitivity analysis.
- Moderna and Merck plan to submit regulatory filings, with Moderna targeting a commercial launch in 2027.
On October 22, 2026, Moderna and Merck reported that their investigational individualized mRNA cancer vaccine reduced the risk of disease recurrence or death by 42 percent in patients with high-risk melanoma who had undergone surgery. The late-breaking findings from the global Phase 3 INTerpath-001 trial evaluate the synthetic mRNA candidate, intismeran autogene, administered alongside Merck's checkpoint inhibitor Keytruda, according to detailed trial disclosures published by Merck.
The companies released the clinical trial data two days earlier than planned after embargoed figures leaked on social media and the cancer news site Oncology Central, as reported by Morningstar. The findings had been scheduled for initial presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid, where the trial was accepted for a presidential symposium presentation and accepted for publication in The New England Journal of Medicine.
INTerpath-001 Phase 3 Trial Results
The INTerpath-001 study enrolled 1,137 patients with stage IIB to stage IV cutaneous melanoma that had been completely removed by surgery. Following surgery, participants were randomized in a two-to-one ratio to receive either intismeran in combination with Keytruda or Keytruda with a placebo, according to the Merck announcement. Patients received intismeran at a 1 mg dose every three weeks for up to nine doses, while Keytruda was administered at 400 mg every six weeks for up to nine cycles, covering roughly one year of treatment.
After a median follow-up of 24.6 months, the combination met its primary endpoint of recurrence-free survival (RFS). The intismeran-Keytruda regimen delivered a 42 percent relative reduction in the risk of recurrence or death compared to Keytruda alone (hazard ratio 0.58; 95% CI, 0.45–0.75; p<0.001). At two years, 82.2 percent of patients receiving the combination were alive without recurrence, compared to 70.0 percent in the Keytruda-only group.
The trial also met its key secondary endpoint of distant metastasis-free survival (DMFS), showing a 38 percent reduction in the risk of distant metastasis or death (hazard ratio 0.62; 95% CI, 0.45–0.85; p=0.002). Two years after treatment, 88.5 percent of combination patients remained free of distant spread, compared to 80.2 percent of those who received Keytruda alone, as detailed by Ars Technica. Data on overall survival remain immature, though the companies reported an observed favorable trend.
Engineering an Individualized Neoantigen Therapy
Intismeran autogene—also tracked as mRNA-4157 and V940—is an individualized neoantigen therapy designed around the genetic profile of each patient's tumor. Scientists sequence the DNA of a patient's tumor cells alongside healthy tissue to identify up to 34 unique cancer-specific mutations known as neoantigens, according to Time.
These patient-specific genetic instructions are encoded into synthetic messenger RNA and encapsulated within lipid nanoparticles, using a manufacturing process related to the platform Moderna deployed for its COVID-19 vaccine. Once injected, the mRNA instructs the patient's cells to produce the neoantigen proteins, stimulating T cells to identify and attack residual cancer cells bearing those specific markers.
Keytruda acts complementarily by inhibiting the PD-1 receptor pathway. By blocking PD-1 interactions with the PD-L1 and PD-L2 ligands, the monoclonal antibody prevents tumor cells from using natural biological checkpoints to deactivate immune cells. While Keytruda releases the immune system's brakes, intismeran supplies the target profile, teaching T cells what to hunt.
Phase 2 Comparisons and Immune Activation Timing
The Phase 3 efficacy figures align closely with expectations while landing slightly below earlier Phase 2 benchmarks, according to BioPharma Dive. In the smaller Phase 2b KEYNOTE-942 trial, five-year follow-up data presented at the 2026 ASCO Annual Meeting demonstrated a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in distant metastasis or death.
Dr. David Berman, chief development officer at Moderna, told Time that the Phase 3 trial evaluated a broader, more diverse patient population than Phase 2, which led researchers to anticipate a potentially muted effect. Trial data indicated that the combination's efficacy required time to manifest. During the first six months of treatment, outcomes between the combination and Keytruda monotherapy were virtually identical, showing an RFS hazard ratio of 0.99.
After six months—marking the completion of the nine-dose intismeran immunization schedule—a pre-specified sensitivity analysis revealed a 58 percent reduction in the risk of recurrence or death (hazard ratio 0.42; 95% CI, 0.30–0.58) and a 50 percent reduction in distant metastasis or death. Berman noted that this delay illustrates the biological time necessary for the immune system to generate and expand customized T-cell populations.
Safety Profile and Market Reaction
The safety profile of intismeran plus Keytruda was generally consistent with previously reported studies of the combination, and no new safety signals were observed. Treatment-related adverse events occurred in 95.8 percent of patients receiving the combination compared to 90.0 percent receiving Keytruda alone, according to the Merck trial release. Grade 3 to 5 treatment-related adverse events occurred in 14.2 percent of combination patients versus 13.4 percent on Keytruda monotherapy.
The most common side effects linked to intismeran were pyrexia (52.2 percent), injection site pain (51.0 percent), and fatigue (38.5 percent). Treatment discontinuation due to adverse events was 7 percent for the combination compared to 5 percent for the control group.
Despite the positive clinical outcome, market reaction was sharp. Following the unapproved leak of the data on Thursday, Moderna shares closed down 17.6 percent, while Merck shares fell approximately 1.7 percent, as reported by Reuters via WHBL. Moderna shares had nearly quadrupled between August—when the trial's success was first disclosed without detailed metrics—and Wednesday's close.
Analysts attributed the drop to a combination of profit-taking and tempered expectations regarding how easily neoantigen therapies will translate to cancers with lower mutational burdens. While melanoma responds relatively well to immunotherapy because of its high mutation rate, RBC Capital Markets analyst Trung Huynh noted that the results represented the low end of investor expectations, writing that commercial expansion into other solid tumors remains less certain.
Regulatory Timelines and Pipeline Expansion
Moderna and Merck confirmed they are engaging with global regulatory authorities to seek approval for intismeran autogene in the adjuvant melanoma setting, according to BioPharma Dive. Moderna CEO Stéphane Bancel stated that the companies expect to launch the treatment commercially in 2027.
The INTerpath clinical development program now encompasses nine active Phase 2 and Phase 3 trials across multiple tumor types. The pipeline includes three Phase 3 studies in non-small cell lung cancer (NSCLC), along with studies exploring intismeran combinations and monotherapies in renal cell carcinoma, bladder cancer, pancreatic ductal adenocarcinoma, and gastric carcinoma. Berman highlighted that because mRNA manufacturing relies on enzymatic synthesis rather than cell cultures, Moderna can produce bespoke patient formulations within weeks, providing a scalable structure as trials progress into broader oncological indications.
Questions people ask
What is intismeran autogene?
Intismeran autogene (mRNA-4157/V940) is an investigational individualized mRNA cancer therapy developed by Moderna and Merck. It sequences a patient's tumor to deliver synthetic mRNA encoding up to 34 patient-specific neoantigens, training the immune system to target residual cancer cells.
What were the primary results of the Phase 3 INTerpath-001 trial?
The trial showed that intismeran combined with Keytruda reduced the risk of melanoma recurrence or death by 42% compared to Keytruda alone over a median follow-up of 24.6 months. Distant metastasis or death was reduced by 38%.
When do Moderna and Merck anticipate making the vaccine available?
Moderna CEO Stéphane Bancel stated that the companies are preparing regulatory filings and expect a commercial launch in 2027, subject to health authority approvals.
Sources
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%Ars Technica, Oct 22, 2026
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumMerck.com, Oct 22, 2026
- Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall1330 & 101.5 WHBL, Oct 22, 2026
- A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%Time, Oct 22, 2026
- Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsBioPharma Dive, Oct 22, 2026
- Moderna's cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbledMorningstar, Inc., Oct 22, 2026
- Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trialSTAT, Oct 22, 2026
How this story was made: the newsroom picked it up from Reddit, gathered the full text of the sources above, and drafted it with AI assistance. Every factual claim was then checked against those sources before publishing (36 claims checked). Illustrations marked as AI-generated are not photographs. Spotted an error? Tell us.
Published October 23, 2026 at 00:46 UTC
